Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to CHF 105 from CHF 100 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis AG: Balancing Promising Pipeline Developments with Valuation and Risk Concerns
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Novartis Stock (NVS) Beats Harder on $5.2B Chinese Heart Disease Deal
- Oppenheimer says Olema collaboration with Pfizer could lead to bidding war
- Arrowhead (ARWR) Stock Soars over $200M Deal with Swiss Pharma Giant Novartis